Overview
Mabion is a European contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, including drug substance manufacturing, analytics, and fill & finish processes. The company offers end-to-end development services from gene to vial, as well as cell line development and banking. Mabion collaborates with various pharmaceutical companies on projects such as the development of antibody-drug conjugates (ADCs) and analytical method development.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 7.83
- High
- PLN 8.02
- Low
- PLN 7.83
- Volume
- 8.91K
- Avg. vol.
- 20.74K
- Market cap
- PLN 128.81M
- P/E ratio
- –
- EPS
- -PLN 3.50
- Shares outstanding
- 16.16M
- 52-week
- PLN 7.64 – 8.17
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLMBION00016
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 881.42k | USD -3.73m | USD -4.03m |
| Q1 2026 | USD 1.23m | USD -2.48m | USD -2.63m |
| Q4 2025 | USD 1.43m | USD -5.06m | USD -5.32m |
| Q3 2025 | USD 1.03m | USD -2.69m | USD -2.70m |
Results for Q3 2026:Nov 17, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
ESG Week 2026 in Mabion
ESG Week 2026 enabled Mabion employees to learn how to safely care for the environment, the ecosystem and themselves.
Open Immunogenicity Database for Biological Therapies Now Available
Immunogenicity Database Collaborative makes immunogenicity data associated with biological therapeutics available for free.
Mabion Experts Nominated for the Life Science Sales and Marketing Awards 2026
Read about the Mabion experts who have been nominated for the Life Science Sales and Marketing Awards 2026.
Mabion expert will conduct workshops on digital transformation in GMP
Amanda Jabłońska will lead a webinar and training session for pharmaceutical companies on digital transformation in GMP environment.
Breakthrough in the treatment of Huntington’s disease
AAV gene therapy for Huntington's disease nears FDA and MHRA approval. AMT-130 is a drug delivered directly into the deep parts of the brain.
Jakub Knurek once again among the TOP 5 Future Leaders at the CPHI Pharma Awards
Jakub Knurek is a Future Leader in the Biopharmaceutical Industry. Our expert was a finalist in the 2026 CPHI Pharma Awards in this category.
Industry
Bank accounts
Registered as a VAT taxpayer on 2007-06-01. Active
61 1090 1304 0000 0001 4958 5216- 02 1090 1304 0000 0001 3453 2945
02 1140 1108 0000 3129 5400 1001
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 15, 2025 | Bankruptcy notice | |
| Jan 22, 2020 | Bankruptcy sale | |
| Nov 2, 2018 | Bankruptcy notice | |
| Jun 7, 2010 | Shareholders' meeting convened | |
| Mar 26, 2010 | Shareholders' meeting convened |
Public aid
15 public aid cases recorded, with a total value of $19,962,995.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 16, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Dec 2, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Dec 2, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2021-09-18 | Opracowanie panelu metod analitycznych do charakterystyki immunogenności w badaniu klinicznym skierowanym do pacjentów cierpiących na reumatoidalne zapalenie stawów z wykorzystaniem rituximabu jako substancji leczniczej. | $538.4K$538,425 | Regionalny Program Operacyjny Województwa Łódzkiego na lata 2014-2020 | |
| 2017-08-01 | Rozwój leku biotechnologicznego poprzez opracowanie innowacyjnego przeciwciała monoklonalnego podklasy IgG1 o obniżonej zawartości niekorzystnych glikoform względem leku referencyjnego – skierowanego przeciwko EGFR | $7.4M$7,442,721 | Program Operacyjny Inteligentny Rozwój | |
| 2016-11-01 | Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych. | $6.8M$6,834,236 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Trademarks
Mabion holds 1 active trademark registered with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2010.
| Mark | Protected until | |
|---|---|---|
| MABION(word) | Sep 28, 2030 | |
| mabion people and ideas of biotech | – |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | Integrated permit | Active |
Authorized Representatives
Manner of representation
The following are authorized to make declarations of will on behalf of the company: two members of the management board acting jointly or one member of the management board acting jointly with a commercial proxy.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Mabion.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Polpharma BiologicsS.A. | $19,057,541.37 | polpharmabiologics.com | ||
| MPR Labssp. z o.o. | $833,714.20 | mpr-labs.com | ||
| BiottsS.A. | $372,115.60 | biotts.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Nexbiosp. z o.o. | $186,582.40 | nexbio.pl | ||
| FcbiotechS.A. | $148,945.77 | fcbiotech.pl | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| Jotachemsp. z o.o. | $6,512.58 | jotachem.pl | ||
| Fusiomicasp. z o.o. | $5,263.98 | fusiomica.com | ||
| MolecureS.A. | $10.77 | molecure.com |
Change history
| Date | Event | |
|---|---|---|
| 2022-11-29 | Share capital change (1,616,182.60 PLN → 1,616,232.60 PLN) | |
| 2022-04-20 | Share capital change (1,616,132.60 PLN → 1,616,182.60 PLN) | |
| 2021-04-02 | Share capital change (1,373,027.20 PLN → 1,616,132.60 PLN) | |
| 2020-06-18 | Share capital change (1,372,077.20 PLN → 1,373,027.20 PLN) | |
| 2018-04-30 | Share capital change (1,180,000.00 PLN → 1,372,077.20 PLN) |
FAQ
Last updated: 2026-08-10